Pieris Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Kathleen Goin, Chief Operating Officer of Pieris Pharmaceuticals, Inc., sold 4,302 shares of common stock on July 15, 2026.
Palvella Therapeutics, Inc. reports that Director Matthew Pauls acquired 6,000 stock options with an exercise price of $154.84.
Matthew E. Korenberg, CFO and Treasurer of Paltella Therapeutics, Inc., reported the acquisition of 1,000 shares of common stock via the exercise of stock options.
Director Christopher P. Kiritsy was granted 3,000 stock options in Palvella Therapeutics, Inc. on June 10, 2026.
Director George M. Jenkins was granted 3,000 stock options in Palvella Therapeutics, Inc. as part of a standard equity incentive.
Director John Doux was granted 3,000 stock options in Palvella Therapeutics, Inc. as part of standard equity compensation.
Chief Operating Officer Kathleen Goin exercised and sold shares of Palvella Therapeutics under a pre-arranged 10b5-1 trading plan.
Chief Operating Officer Kathleen Goin exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Palvella Therapeutics Director John Doux acquired 6,000 stock options with an exercise price of $129, vesting over 36 months.
Palvella Therapeutics Director George M. Jenkins acquired 4,000 shares of common stock for $125 per share in an underwritten offering.
Palvella Therapeutics Director Elaine J. Heron purchased 2,400 shares of common stock for $125 per share in an underwritten offering.
Palvella Therapeutics' Chief Scientific Officer, Jeffrey S. Martini, was granted 64,318 stock options with an exercise price of $76.43, vesting over 48 months.
Palvella Therapeutics' Chief Commercial Officer, Ashley Hartmann Kline, was granted 38,517 stock options with an exercise price of $76.43.
Palvella Therapeutics' President and CEO, Wes Kaupinen, was granted 124,603 stock options with an exercise price of $76.43, vesting over four years.
Palvella Therapeutics CFO Matthew Korenberg was granted 44,123 stock options with an exercise price of $76.43, vesting over 48 months.
Palvella Therapeutics' Chief Operating Officer, Kathleen Goin, was granted 48,956 stock options with an exercise price of $76.43, vesting over four years.
Palvella Therapeutics' Chief Operating Officer, Kathleen Goin, executed a pre-planned sale of common stock following the exercise of stock options.
Palvella Therapeutics COO Kathleen Goin exercised stock options and sold 4,302 shares of common stock for investment diversification under a 10b5-1 plan.
Palvella Therapeutics' Chief Operating Officer, Kathleen Goin, executed pre-planned option exercises and subsequent sales of common stock totaling 4,302 shares.
Palvella Therapeutics, Inc. director Tadd S. Wessel was granted 12,350 non-qualified stock options with an exercise price of $26.23, as reported in a recent SEC Form 4 filing.
Palvella Therapeutics, Inc. Director Christopher P. Kiritsy was granted 12,350 non-qualified stock options with an exercise price of $26.23, as disclosed in a recent SEC Form 4 filing.
Palvella Therapeutics, Inc. Director George M. Jenkins was granted 12,350 non-qualified stock options with an exercise price of $26.23, exercisable from June 10, 2026.
Palvella Therapeutics, Inc. Director Elaine J. Heron has acquired 12,350 non-qualified stock options with an exercise price of $26.23, aligning her interests with the company's future performance.
Palvella Therapeutics, Inc. director Todd C. Davis was granted 12,350 non-qualified stock options with an exercise price of $26.23, exercisable from June 10, 2026.
Palvella Therapeutics, Inc.'s Chief Commercial Officer, Ashley Hartmann Kline, was granted 128,932 stock options with an exercise price of $22.94, vesting over a four-year period.
Director George M. Jenkins reports purchasing additional shares of Palvella Therapeutics, increasing his direct and indirect holdings.
Wes Kaupinen, President and CEO of Palvella Therapeutics, acquired 243,831 non-qualified stock options on February 5, 2025.
Jeffrey S. Martini, Chief Scientific Officer of Palvella Therapeutics, acquired incentive and non-qualified stock options on February 5, 2025.
Kathleen Goin, Chief Operating Officer of Palvella Therapeutics, received incentive and non-qualified stock options on February 5, 2025.
Matthew E. Korenberg, CFO and Treasurer of Palvella Therapeutics, reports the acquisition of incentive and non-qualified stock options.